Collegium Launches $50M Accelerated Buyback at $25.70, 80% of Shares Delivered
COLL is trading near its 52-week low of $25.47 (2.3% above the low) on elevated volume (2.4× avg).
Summary
Collegium entered a $50 million accelerated share repurchase agreement with Jefferies, receiving 1.56 million shares upfront at $25.70 — about 80% of the expected total. The buyback is part of the $150 million program authorized in July 2025, leaving $100 million remaining. The company is trading near its 52-week low of $25.47, and management explicitly says the valuation does not reflect the strength of its ADHD portfolio and pain business. This follows Q2 results on August 6 that showed 6% revenue growth but a net loss from Azstarys acquisition costs. The ASR removes roughly 4.8% of shares outstanding immediately, a meaningful signal of insider confidence at depressed prices. Final settlement is expected by Q4 2026.
At the time of this announcement, COLL was trading at $26.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $836.7M. The 52-week trading range was $25.47 to $50.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.